Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, June 9, 2026, 1:00–2:00 PM ET
In this webinar, we will examine how immune recognition after allogeneic HCT can influence leukemia relapse and disease progression. The session will highlight the clinical relevance of HLA loss of heterozygosity (LOH), approaches used for its detection, and how LOH findings may support transplant strategies, including considerations for donor selection in subsequent transplantation.
Webinar presenter Alberto Cardoso Martins Lima, PhD, Clinical consulting scientist in histocompatibility,
specializing in allogeneic hematopoietic cell transplantation (HCT) at IGEN/AFIP São Paulo and CHC/UFPR in Curitiba, Brazil
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, June 24, 2026, 12:00–1:00 PM ET
Hear an expert discuss the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer and its impact on your practice
Webinar presenter Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
December 2013—BioTheranostics announced that Mayo Clinic and Mayo Medical Laboratories will offer the company’s CancerType ID molecular cancer classification test to aid in the management of patients with metastatic cancer.
December 2013—Quidel and Life Technologies announced that the FDA has granted 510(k) clearances to the Quidel Molecular Influenza A+B assay and the Quidel Molecular RSV+hMPV assay, both for use on the QuantStudio Dx Real-Time PCR instrument by Life Technologies.
December 2013—Novartis announced a definitive agreement to sell its blood transfusion diagnostics unit to Grifols for $1.675 billion. The transaction is expected to be completed in the first half of 2014.
December 2013—Myriad Genetics launched a new prognostic test, Myriad myPlan Lung Cancer, for patients diagnosed with early stage lung adenocarcinoma. MyPlan Lung Cancer is an RNA expression panel of 31 cell-cycle-progression genes in combination with tumor staging information to determine a patient’s risk of dying from lung cancer within five years.
December 2013—Illumina announced the launch of its TruGenome Undiagnosed Disease Test provided by the CLIA-certified, CAP-accredited Illumina Clinical Services Laboratory. This new service uses whole genome sequencing to assist physicians in identifying the underlying genetic cause of a rare or undiagnosed disease.
December 2013—Bio SB, a molecular pathology company based in Santa Barbara, Calif., announced the launch of its Bcl-6 rabbit monoclonal antibody for in vitro diagnostic use. Bcl-6 is a transcriptional regulator gene that codes for a 706-amino-acid nuclear zinc finger protein.
December 2013—Quest Diagnostics now offers BRCAvantage, a suite of four lab-developed genetic tests that identify mutations in BRCA1 and BRCA2 genes. The BRCAvantage test is performed using next-generation sequencing and multiplex ligation-dependent probe amplification to detect all published deleterious mutations in BRCA1 and BRCA2.
December 2013—Microbiologics, a St. Cloud, Minn.-based company, has acquired Phthisis Diagnostics. Phthisis’ innovative, patented G-Sphere molecular standards product line will be the foundation for Microbiologics’ move into molecular products and a new division it is forming. G-Sphere standards are synthetic genes that provide controls for virtually any organism or molecular assay.
December 2013—Transgenomic has entered into a collaborative agreement with PerkinElmer to market and distribute Transgenomic’s oncology diagnostic test portfolio of products in territories outside the United States.
The Legato 110 DRS (dual-rate syringe) pump system offers researchers complete flexibility to start two pumps simultaneously for delivery of two independent flow rates.
